Abstract

Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by thrombosis, pregnancy morbidity, or nonthrombotic manifestations in patients with persistently positive antiphospholipid antibodies (aPL). Conventional APS treatment focuses on antithrombotic strategies, which are usually ineffective for the microvascular and nonthrombotic manifestations of aPL. Using a case-based presentation, this review focuses on the role of immunosuppression in nonobstetric APS, including B-cell inhibition (rituximab, belimumab, and bortezomib), complement inhibition (eculizumab), mechanistic target of rapamycin inhibition (sirolimus), vascular endothelial cell modulation (defibrotide), statins, and traditional rheumatologic disease–modifying agents (hydroxychloroquine, mycophenolate mofetil, azathioprine, and cyclophosphamide).

References

References
1.
Miyakis
S
,
Lockshin
MD
,
Atsumi
T
, et al
.
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
.
J Thromb Haemost
.
2006
;
4
(
2
):
295
-
306
.
2.
Legault
K
,
Schunemann
H
,
Hillis
C
, et al
.
McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome
.
J Thromb Haemost
.
2018
;
16
(
8
):
1656
-
1664
.
3.
Garcia
D
,
Erkan
D
.
Diagnosis and management of the antiphospholipid syndrome
.
N Engl J Med
.
2018
;
378
(
21
):
2010
-
2021
.
4.
Erkan
D
,
Yazici
Y
,
Peterson
MG
,
Sammaritano
L
,
Lockshin
MD
.
A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome
.
Rheumatology (Oxford)
.
2002
;
41
(
8
):
924
-
929
.
5.
Willis
R
,
Cohen
H
,
Giles
I
, et al
.
Mechanisms of antiphospholipid antibody-mediated thrombosis
. In:
Erkan
D
,
Lockshin
MD
, eds.
Antiphospholipid Syndrome Current Research Highlights and Clinical Insights
.
New York
:
Springer
;
2017
:
77
-
116
.
6.
Agar
C
,
van Os
GM
,
Mörgelin
M
, et al
.
β2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome
.
Blood
.
2010
;
116
(
8
):
1336
-
1343
.
7.
Willis
R
,
Gonzalez
EB
,
Brasier
AR
.
The journey of antiphospholipid antibodies from cellular activation to antiphospholipid syndrome
.
Curr Rheumatol Rep
.
2015
;
17
(
3
):
16
.
8.
Rodríguez-Pintó
I
,
Espinosa
G
,
Erkan
D
,
Shoenfeld
Y
,
Cervera
R
;
CAPS Registry Project Group
.
The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients
.
Rheumatology (Oxford)
.
2018
;
57
(
7
):
1264
-
1270
.
9.
Unlu
O
,
Erkan
D
.
Catastrophic antiphospholipid syndrome: candidate therapies for a potentially lethal disease
.
Annu Rev Med
.
2017
;
68
(
1
):
287
-
296
.
10.
Youinou
P
,
Renaudineau
Y
.
The antiphospholipid syndrome as a model for B cell-induced autoimmune diseases
.
Thromb Res
.
2004
;
114
(
5-6
):
363
-
369
.
11.
Kahn
P
,
Ramanujam
M
,
Bethunaickan
R
, et al
.
Prevention of murine antiphospholipid syndrome by BAFF blockade
.
Arthritis Rheum
.
2008
;
58
(
9
):
2824
-
2834
.
12.
Adachi
Y
,
Inaba
M
,
Sugihara
A
, et al
.
Effects of administration of monoclonal antibodies (anti-CD4 or anti-CD8) on the development of autoimmune diseases in (NZW x BXSB)F1 mice
.
Immunobiology
.
1998
;
198
(
4
):
451
-
464
.
13.
Simonin
L
,
Pasquier
E
,
Leroyer
C
, et al
.
lymphocyte disturbances in primary antiphospholipid syndrome and application to venous thromboembolism follow-up
.
Clin Rev Allergy Immunol
.
2017
;
53
(
1
):
14
-
27
.
14.
Ugolini-Lopes
MR
,
Criado
PR
,
Parsi
K
, et al
.
Treatment of non-criteria manifestations in antiphospholipid syndrome
. In:
Erkan
D
,
Lockshin
MD
, eds.
Antiphospholipid Syndrome Current Research Highlights and Clinical Insights
.
New York
:
Springer
;
2017
:
247
-
266
15.
Erkan
D
,
Vega
J
,
Ramón
G
,
Kozora
E
,
Lockshin
MD
.
A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome
.
Arthritis Rheum
.
2013
;
65
(
2
):
464
-
471
.
16.
Berman
H
,
Rodríguez-Pintó
I
,
Cervera
R
, et al
;
Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (European Forum on Antiphospholipid Antibodies)
.
Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab
.
Autoimmun Rev
.
2013
;
12
(
11
):
1085
-
1090
.
17.
Aguiar
C
,
Lehman
T
,
Erkan
D
.
Rituximab use in pediatric antiphospholipid antibody positive patients [abstract]
.
Arthritis Rheum
.
2014
;
66
:
S142
.
Abstract 106
.
18.
Yazici
A
,
Yazirli
B
,
Erkan
D
.
Belimumab in primary antiphospholipid syndrome
.
Lupus
.
2017
;
26
(
10
):
1123
-
1124
.
19.
Sciascia
S
,
Rubini
E
,
Radin
M
,
Cecchi
I
,
Rossi
D
,
Roccatello
D
.
Anticardiolipin and anti-beta 2 glycoprotein-I antibodies disappearance in patients with systemic lupus erythematosus and antiphospholipid syndrome while on belimumab
.
Ann Rheum Dis
.
2018
;
77
(
11
):
1694
-
1695
.
20.
Emmi
G
,
Bettiol
A
,
Palterer
B
, et al
.
Belimumab reduces antiphospholipid antibodies in SLE patients independently of hydroxychloroquine treatment
.
Autoimmun Rev
.
2019
;
18
(
3
):
312
-
314
.
21.
Pellom
ST
Jr
,
Dudimah
DF
,
Thounaojam
MC
,
Sayers
TJ
,
Shanker
A
.
Modulatory effects of bortezomib on host immune cell functions
.
Immunotherapy
.
2015
;
7
(
9
):
1011
-
1022
.
22.
Tkachenko
O
,
Lapin
S
,
Maslyansky
A
,
Myachikova
V
,
Mikhailova
L
,
Gilburd
B
.
Relapsing Evans syndrome and systemic lupus erythematosus with antiphospholipid syndrome treated with Bortezomib in combination with plasma exchange
.
Clin Immunol
.
2019
;
199
:
44
-
46
.
23.
Redecha
P
,
Tilley
R
,
Tencati
M
, et al
.
Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury
.
Blood
.
2007
;
110
(
7
):
2423
-
2431
.
24.
Chaturvedi
S
,
Brodsky
RA
,
McCrae
KR
.
complement in the pathophysiology of the antiphospholipid syndrome
.
Front Immunol
.
2019
;
10
:
449
.
25.
Pierangeli
SS
,
Girardi
G
,
Vega-Ostertag
M
,
Liu
X
,
Espinola
RG
,
Salmon
J
.
Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia
.
Arthritis Rheum
.
2005
;
52
(
7
):
2120
-
2124
.
26.
Erkan
D
,
Salmon
JE
.
The role of complement inhibition in thrombotic angiopathies and antiphospholipid syndrome
.
Turk J Haematol
.
2016
;
33
(
1
):
1
-
7
.
27.
Kello
N
,
Khoury
LE
,
Marder
G
,
Furie
R
,
Zapantis
E
,
Horowitz
DL
.
Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: case series and review of literature
.
Semin Arthritis Rheum
.
2019
;
49
(
1
):
74
-
83
.
28.
Park
MH
,
Caselman
N
,
Ulmer
S
,
Weitz
IC
.
Complement-mediated thrombotic microangiopathy associated with lupus nephritis
.
Blood Adv
.
2018
;
2
(
16
):
2090
-
2094
.
29.
de Holanda
MI
,
Pôrto
LC
,
Wagner
T
,
Christiani
LF
,
Palma
LMP
.
Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review
.
Clin Rheumatol
.
2017
;
36
(
12
):
2859
-
2867
.
30.
Kronbichler
A
,
Frank
R
,
Kirschfink
M
, et al
.
Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report
.
Medicine (Baltimore)
.
2014
;
93
(
26
):
e143
.
31.
Hütt-Cabezas
M
,
Karajannis
MA
,
Zagzag
D
, et al
.
Activation of mTORC1/mTORC2 signaling in pediatric low-grade glioma and pilocytic astrocytoma reveals mTOR as a therapeutic target
.
Neuro-oncol
.
2013
;
15
(
12
):
1604
-
1614
.
32.
Xia
L
,
Zhou
H
,
Wang
T
, et al
.
Activation of mTOR is involved in anti-β2GPI/β2GPI-induced expression of tissue factor and IL-8 in monocytes
.
Thromb Res
.
2017
;
157
:
103
-
110
.
33.
Hollerbach
A
,
Müller-Calleja
N
,
Ritter
S
, et al
.
Platelet activation by antiphospholipid antibodies depends on epitope specificity and is prevented by mTOR inhibitors
.
Thromb Haemost
.
2019
;
119
(
07
):
1147
-
1153
.
34.
Canaud
G
,
Bienaimé
F
,
Tabarin
F
, et al
.
Inhibition of the mTORC pathway in the antiphospholipid syndrome
.
N Engl J Med
.
2014
;
371
(
4
):
303
-
312
.
35.
Sevim
E
,
Siddique
S
,
Chyou
S
, et al
.
Mammalian target of rapamycin (mTOR) pathway assessment in antiphospholipid antibody positive patients with livedo reticularis/racemosa [abstract]
.
Arthritis Rheumatol
.
2018
;
70
(
suppl 10
):168-169.
Abstract
162.
36.
Badger
A
,
Sevim
E
,
Alpan
O
, et al
.
Flow cytometric assessment of the mammalian target of rapamycin pathway using antiphospholipid syndrome as a disease model [abstract]
.
Arthritis Rheumatol
.
2018
;
70
(
suppl 10
):179-180.
Abstract
171.
37.
Sartorelli
S
,
De Luca
G
,
Campochiaro
C
, et al
.
Successful use of sirolimus in a patient with cardiac microangiopathy in primary antiphospholipid syndrome
.
Scand J Rheumatol
.
2019
;
1
-
2
.
38.
Bruschi
M
,
Petretto
A
,
Bertelli
R
, et al
.
Post-translational modified proteins are biomarkers of autoimmune-processes: NETosis and the inflammatory-autoimmunity connection
.
Clin Chim Acta
.
2017
;
464
:
12
-
16
.
39.
Pescador
R
,
Porta
R
,
Ferro
L
.
Defibrotide and endothelial cell activation
.
Cardiovasc Drug Rev
.
2006
;
18
(
4
):
304
-
311
.
40.
Corbacioglu
S
,
Carreras
E
,
Mohty
M
, et al
.
Defibrotide for the treatment of hepatic veno-occlusive disease: final results from the international compassionate-use program
.
Biol Blood Marrow Transplant
.
2016
;
22
(
10
):
1874
-
1882
.
41.
Falanga
A
,
Vignoli
A
,
Marchetti
M
,
Barbui
T
.
Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells
.
Leukemia
.
2003
;
17
(
8
):
1636
-
1642
.
42.
Ali
RA
,
Gandhi
AA
,
Meng
H
, et al
.
Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome
.
Nat Commun
.
2019
;
10
(
1
):
1916
.
43.
Burcoglu-O’Ral
A
,
Erkan
D
,
Asherson
R
.
Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator
.
J Rheumatol
.
2002
;
29
(
9
):
2006
-
2011
.
44.
Meroni
PL
,
Raschi
E
,
Testoni
C
, et al
.
Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype
.
Arthritis Rheum
.
2001
;
44
(
12
):
2870
-
2878
.
45.
López-Pedrera
C
,
Ruiz-Limón
P
,
Aguirre
MA
, et al
.
Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome
.
Ann Rheum Dis
.
2011
;
70
(
4
):
675
-
682
.
46.
Erkan
D
,
Willis
R
,
Murthy
VL
, et al
.
A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients
.
Ann Rheum Dis
.
2014
;
73
(
6
):
1176
-
1180
.
47.
Belizna
C
.
Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome
.
Autoimmun Rev
.
2015
;
14
(
4
):
358
-
362
.
48.
Schmidt-Tanguy
A
,
Voswinkel
J
,
Henrion
D
, et al
.
Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients
.
J Thromb Haemost
.
2013
;
11
(
10
):
1927
-
1929
.
49.
Allison
AC
,
Eugui
EM
.
Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil
.
Immunol Rev
.
1993
;
136
(
1
):
5
-
28
.
50.
Maltzman
JS
,
Koretzky
GA
.
Azathioprine: old drug, new actions
.
J Clin Invest
.
2003
;
111
(
8
):
1122
-
1124
.
51.
Bayraktar
UD
,
Erkan
D
,
Bucciarelli
S
,
Espinosa
G
,
Asherson
R
;
Catastrophic Antiphospholipid Syndrome Project Group
.
The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus
.
J Rheumatol
.
2007
;
34
(
2
):
346
-
352
.
52.
Pazzola
G
,
Zuily
S
,
Erkan
D
.
The challenge of bleeding in antiphospholipid antibody-positive patients
.
Curr Rheumatol Rep
.
2015
;
17
(
2
):
7
.
53.
Cartin-Ceba
R
,
Peikert
T
,
Ashrani
A
, et al
.
Primary antiphospholipid syndrome-associated diffuse alveolar hemorrhage
.
Arthritis Care Res (Hoboken)
.
2014
;
66
(
2
):
301
-
310
.
54.
Asherson
RA
,
Cervera
R
,
de Groot
PG
, et al
;
Catastrophic Antiphospholipid Syndrome Registry Project Group
.
Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines
.
Lupus
.
2003
;
12
(
7
):
530
-
534
.
55.
Ben Salem
C
.
The pathogenesis of the antiphospholipid syndrome
.
N Engl J Med
.
2013
;
368
(
24
):
2334
-
2335
.
You do not currently have access to this content.